- Rating
- 2
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper proposes Risk-Pro for multimodal cancer survival prediction. It augments a pathology-genomics conditional VAE with risk-associated prototype supervision. Prototypes are constructed from average genomic features within outcome-defined patient groups, using only the training fold. The model reconstructs both individual genomic features and the corresponding group prototypes, while a risk-distance-weighted cosine objective regularizes relationships between prototypes. Cross-attention and gated pooling produce survival predictions. Experiments use five-fold cross-validation across six TCGA cancer cohorts, including complete-modality and gene-missing inference.
Critical strengths
The experimental evaluation covers six cancer cohorts and includes both complete-modality and gene-missing settings. The component ablations separately examine prototype reconstruction and the progressive constraint, and the paper also evaluates sensitivity to prototype granularity and loss weights.
Critical weaknesses
-
The methodological advance over closely related risk-prototype methods is insufficiently established. The paper motivates its contribution by suggesting that existing approaches overlook population-level risk structures and that prior prototypes mainly compress features. However, PIBD (Zhang et al., ICLR 2024) already learns prototypes associated with risk bands defined by survival time and censoring status. The cross-modal generative backbone also follows LD-CVAE. The specific additions therefore appear to be outcome-group mean reconstruction targets and a risk-distance-weighted prototype regularizer. These differences need to be positioned more precisely. Comparing complete architectures in Table 1 does not isolate their contribution relative to established risk-prototype supervision applied within the same backbone.
-
The central progressive-risk mechanism is not sufficiently justified. When minimized, Equation (8) penalizes cosine similarity for every pair of distinct prototypes, with larger weights for more distant risk levels. It contains no explicit adjacent-prototype attraction or relative-similarity ordering constraint. The authors needs to establish that its benefit comes specifically from correct risk ordering, rather than generic prototype separation.
Questions for authors
-
What is the specific methodological distinction between the proposed risk-associated prototypes and PIBD’s risk-band-conditioned prototypes? Please add a matched-backbone comparison between the proposed prototype supervision and PIBD-style risk-prototype supervision to isolate the contribution of the proposed design.
-
Please explain how minimizing Equation (8) produces the claimed ordinal organization. Can you compare the proposed distance weights against (i) equal weights for all prototype pairs and (ii) weights obtained after randomly permuting the risk-level order?
-
How are censored patients with shorter follow-up handled in prototype construction and the prototype-reconstruction loss? What exactly defines “half of the overall time,” and what justifies the resulting “safe” designation? Please examine whether the improvements persist under an alternative grouping scheme that explicitly accounts for the incomplete outcomes of censored patients.